Beyond Air™
Beyond Air is a medical device and biopharmaceutical company dedicated to harnessing the power of nitric oxide to improve patient lives. They develop innovative systems like LungFit, which generate nitric oxide from room air, eliminating the need for cylinders, and are advancing treatments for respiratory illnesses, neurological disorders, and solid tumors. The company is committed to revolutionizing nitric oxide therapy from hospital to home, with a focus on safety, efficiency, and expanding treatment options.
Industries
Nr. of Employees
small (1-50)
Beyond Air™
Garden City, New York, United States, North America
Patents
Products
Commercial ambient-air nitric oxide generation and delivery system for pulmonary indications
A commercial, tankless therapeutic gas generation and delivery system that produces nitric oxide from ambient air for inhalation therapy; described for treatment of neonatal hypoxic respiratory failure and other pulmonary indications within approved labeling.
Investigational high-concentration nitric oxide delivery systems (research use)
Investigational delivery systems and protocols to administer ultra-high concentrations of nitric oxide for preclinical and clinical research in severe pulmonary infections and oncology (described as investigational and limited to study settings).
LungFit
The LungFit PH generates inhaled nitric oxide (iNO), a selective pulmonary vasodilator, and delivers it into the inspiratory limb of the patient breathing circuit of an ICU ventilator, providing a constant concentration of nitric oxide as set by the user. It is the first and only 3-in-1 integrated system for iNO generation, delivery, and monitoring, generating unlimited, on-demand iNO from room air without the need for pressurized cylinders.
LungFit 4 Technology Platform
A patented Ionization technology platform that generates inhaled nitric oxide (iNO) from room air at doses ranging from 0.1 PPM to 400 PPM.
LungFit At-Home Treatment
A high-concentration inhaled nitric oxide (iNO) delivery system designed for at-home treatment of nontuberculous mycobacteria (NTM) lung infection and chronic obstructive pulmonary disease (COPD) patients with persistent lung infections.
LungFit Hospital NICU Setting
A low-concentration inhaled nitric oxide (iNO) delivery system designed for use in hospital NICU settings to treat term and near-term neonates with hypoxic respiratory failure, commonly referred to as persistent pulmonary hypertension of the newborn (PPHN).
Commercial ambient-air nitric oxide generation and delivery system for pulmonary indications
A commercial, tankless therapeutic gas generation and delivery system that produces nitric oxide from ambient air for inhalation therapy; described for treatment of neonatal hypoxic respiratory failure and other pulmonary indications within approved labeling.
Investigational high-concentration nitric oxide delivery systems (research use)
Investigational delivery systems and protocols to administer ultra-high concentrations of nitric oxide for preclinical and clinical research in severe pulmonary infections and oncology (described as investigational and limited to study settings).
LungFit
The LungFit PH generates inhaled nitric oxide (iNO), a selective pulmonary vasodilator, and delivers it into the inspiratory limb of the patient breathing circuit of an ICU ventilator, providing a constant concentration of nitric oxide as set by the user. It is the first and only 3-in-1 integrated system for iNO generation, delivery, and monitoring, generating unlimited, on-demand iNO from room air without the need for pressurized cylinders.
LungFit 4 Technology Platform
A patented Ionization technology platform that generates inhaled nitric oxide (iNO) from room air at doses ranging from 0.1 PPM to 400 PPM.
LungFit At-Home Treatment
A high-concentration inhaled nitric oxide (iNO) delivery system designed for at-home treatment of nontuberculous mycobacteria (NTM) lung infection and chronic obstructive pulmonary disease (COPD) patients with persistent lung infections.
LungFit Hospital NICU Setting
A low-concentration inhaled nitric oxide (iNO) delivery system designed for use in hospital NICU settings to treat term and near-term neonates with hypoxic respiratory failure, commonly referred to as persistent pulmonary hypertension of the newborn (PPHN).
Services
Establishing and managing international distribution agreements and fulfilling initial international orders for therapeutic gas delivery systems.
Partnerships with academic institutions and research centers to advance preclinical programs (neurological disorders, oncology) and to evaluate mechanisms of action.
Clinical study design, execution and data dissemination support for inhaled nitric oxide therapies, including safety-focused randomized studies and investigator collaborations.
Licensing of intellectual property and development of commercial collaborations for therapeutic indications and technologies.
Establishing and managing international distribution agreements and fulfilling initial international orders for therapeutic gas delivery systems.
Partnerships with academic institutions and research centers to advance preclinical programs (neurological disorders, oncology) and to evaluate mechanisms of action.
Clinical study design, execution and data dissemination support for inhaled nitric oxide therapies, including safety-focused randomized studies and investigator collaborations.
Licensing of intellectual property and development of commercial collaborations for therapeutic indications and technologies.
Expertise Areas
- Inhaled nitric oxide therapy development
- Clinical trial management and execution
- Medical device development and commercialization
- Preclinical research (neurology and oncology)
Key Technologies
- Ambient-air nitric oxide generation (ionizer-based)
- Inhaled nitric oxide delivery systems
- Ventilator-integrated gas delivery
- Ultra-high concentration nitric oxide delivery (intratumoral/oncology research)